Stocks · News reference
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AgomAb Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $60 price target.
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
Aerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.